![]() |
| Source: 3D Systems Q3 2026 Financial Results |
Third-quarter revenue was $99.3 million / Dental materials sales grew by more than 20% / Full-year 2026 revenue growth expected to be near mid-single digits
DentalGoodNews|On November 4, 2026, 3D Systems (NYSE: DDD) reported financial results for the third quarter of 2026. Quarterly revenue was $99.3 million (approximately RMB 667 million), up 8.8% year over year; excluding the impact of the software business divestiture completed in 2025, revenue grew 10.9% year over year. Net loss attributable to the company was $33.5 million (approximately RMB 225 million), compared with $18.1 million (approximately RMB 122 million) in the prior-year period.
Healthcare Solutions third-quarter revenue was $49.0 million (approximately RMB 329 million), up approximately 14.4% year over year. The company said growth in the segment was primarily driven by increased dental materials sales and higher medical parts manufacturing volumes; among these, both dental materials sales and medical parts manufacturing grew by more than 20% year over year in the quarter.
On the earnings call, Chief Executive Officer Jeffrey Graves said dental materials revenue rebounded in the third quarter as clear aligner volumes returned to longer-term run-rate levels; adoption of the company's dental prosthesis printing technology by dental laboratories in the United States and Europe is also increasing. He expects these trends to strengthen further as 3D Printing gradually becomes the standard production method for dental prosthesis manufacturing.
![]() |
| Source: 3D Systems Q3 2026 Financial Results |
On profitability metrics, third-quarter Adjusted EBITDA was $3.1 million (approximately RMB 20.83 million), compared with negative $10.8 million (approximately negative RMB 72.55 million) in the prior-year period, an improvement of $13.9 million (approximately RMB 93.38 million). The company attributed the improvement primarily to prior cost reductions, higher volumes and increased operating leverage. Excluding the impact of the software business divestiture, the prior-year period was negative $10.0 million (approximately negative RMB 67.18 million), corresponding to an improvement of $13.1 million (approximately RMB 88.01 million).
Under Generally Accepted Accounting Principles (GAAP), the company's third-quarter net loss attributable to the company widened. The company said the increased loss was mainly related to litigation expenses, asset impairments, unfavorable foreign exchange effects and unfavorable year-over-year changes in income tax. Adjusted EBITDA is a non-GAAP metric and is calculated with adjustments for items including depreciation and amortization, share-based compensation and certain legal expenses; its turning positive does not mean the company has achieved profitability on a GAAP basis.
On cash flow, in the first three quarters of 2026, the company's net cash used in operating activities was $17.5 million (approximately RMB 118 million). As of September 30, 2026, the company had total cash and investments of $120.5 million (approximately RMB 810 million), including $91.8 million (approximately RMB 617 million) in cash, cash equivalents and restricted cash, $27.1 million (approximately RMB 182 million) in short-term investments, and $1.6 million (approximately RMB 10.75 million) in long-term investments.
Looking ahead to the fourth quarter of 2026, the company expects revenue of $100 million (approximately RMB 672 million) to $103 million (approximately RMB 692 million), and Adjusted EBITDA of a loss of $2 million (approximately a loss of RMB 13.44 million) to break-even. The company said the guidance takes into account normal fluctuations in customer project and investment cycles, as well as a more even distribution of purchasing throughout the year. Based on the midpoint of the fourth-quarter guidance, the company expects full-year 2026 revenue growth to be near mid-single digits.
| About DGN:DentalGoodNews (DGN) is a trusted professional media platform dedicated to the global dental industry. We deliver in-depth coverage of corporate news, policy & regulation, investment & funding, and clinical frontiers — serving dental institutions, device manufacturers, investors, and industry researchers worldwide. Contact us: haodeya@dongxizixun.com |